National Cancer Institute, AbbVie, and Roche's ViPOR Therapy for B-Cell Lymphoma Demonstrates 38% Complete Response Rate in Phase 1/2 Clinical Trials
Innovative Combination Therapy Based on Non-Chemotherapy
The Phase 1/2 clinical trial (NCT03223610), led by the National Cancer Institute (NCI), is an innovative project for patients with relapsed/refractory B-cell lymphoma who have failed standard treatment. Instead of conventional toxic chemotherapy, it introduces a 'ViPOR' combination therapy, which combines five targeted agents to block tumor survival pathways in multiple ways. This therapy is administered for a maximum of six cycles, with each cycle lasting 21 days, and can be administered in an outpatient setting, significantly improving the patient's quality of life. This offers a new clinical alternative, particularly for elderly patients or those who cannot tolerate the side effects of chemotherapy, and has garnered significant attention.
Synergistic Mechanism of Five Targeted Drugs
The five drugs that make up the ViPOR therapy exhibit synergistic effects through their unique mechanisms, overcoming cancer cell resistance. Venetoclax (Venclesta), a B-cell lymphoma 2 (BCL-2) inhibitor, and Ibrutinib (Imbruvica), a Bruton's Tyrosine Kinase (BTK) inhibitor, inhibit key signaling pathways. In addition, Lenalidomide (Revlimid), an immunomodulatory agent, Obinutuzumab (Gazyva), a CD20-targeted antibody, and Prednisone, a steroid, are added to further enhance the immune response. This is an organically combined multi-blockade structure that brings together AbbVie (ABBV), Roche (RHHBY), and Bristol Myers Squibb (BMY)'s leading treatments.
Efficacy Proven in the New England Journal of Medicine (NEJM)
According to the results of the Phase 1b/2 clinical trial recently published in the New England Journal of Medicine (NEJM), among the 48 patients evaluated, an objective response rate (ORR) of 54% and a complete response (CR) of 38% were observed. In particular, the non-germinal center B-cell (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL), which has a poor prognosis, showed excellent response rates. With a median follow-up of 40 months, a 2-year progression-free survival (PFS) of 34% and an overall survival (OS) of 36% were achieved, demonstrating the potential for cure. The toxicity was also limited to manageable side effects such as neutropenia, alleviating safety concerns.
Paradigm Shift in the Competitive Landscape of Lymphoma Treatment
The global market for diffuse large B-cell lymphoma (DLBCL) is estimated at approximately $5 billion (approximately 6.8 trillion Korean Won) and continues to grow. The market is dominated by strong competitors such as Yescarta, a chimeric antigen receptor T-cell (CAR-T) therapy from Gilead, and Columvi, a bispecific antibody from Roche. In this context, ViPOR therapy offers a short-term, intensive treatment regimen with low toxicity using only a combination of existing drugs, without the need for expensive gene therapy. This is expected to serve as a cost-effective bridge for patients who cannot afford high-cost treatments or whose condition rapidly deteriorates during the CAR-T manufacturing waiting period.
The results of this Phase 1/2 clinical trial demonstrate the efficacy of the non-chemotherapy-based ViPOR combination therapy in the $5 billion global diffuse large B-cell lymphoma (DLBCL) market, with an objective response rate (ORR) of 54% and a complete response rate (CR) of 38%, presenting a new combination paradigm. Compared to existing CAR-T therapies such as Gilead's Yescarta, it utilizes a combination of existing drugs that can be administered in an outpatient setting, enhancing treatment accessibility and cost-effectiveness. By demonstrating excellent response in patients with the extremely poor prognosis non-germinal center B-cell (non-GCB) subtype, it directly addresses a significant unmet medical need. In the short term, it is expected to capture the market as a bridging therapy for CAR-T waiting patients, and in the medium to long term, it will lead to increased sales of individual components by multinational pharmaceutical companies such as AbbVie (ABBV), Roche (RHHBY), and BMS (BMY). With its publication in the highly reputable NEJM, multi-target blockade therapies between multinational companies are expected to become a mainstream model for anticancer pipeline development and promote regulatory approvals.
Source: ClinicalTrials.gov (api_ct)